Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 


Immunity drives cancer into permanent growth arrest

Martin Röcken and his team at the Department of Dermatology, Eberhard Karls University Tuebingen, found that anti-cancer immunity is capable of driving cancers and single cancer cells into a permanent growth arrest (1).

Scientifically this permanent growth arrest is called senescence (2, 3). As complete cancer eradication is normally not feasible, deadly metastases normally result from surviving and regrowing cancer cells. The new data now explain, how immunity and immunotherapies can efficiently control surviving cancer cells and thus protect from cancer and metastases (1, 4).

Fig. 1: In red, the expression of a senescence marker in former proliferating melanoma cells that underwent growth arrest. Here, senescence occurred in the context of melanoma regression induced by a natural anti-melanoma immune response. In brown, pigment bearing cells.
University Hospital Tübingen

„The major goal of cancer therapy is the eradication, if possible of all cancer cells. Yet, we have learned over the past 50 years that some cancer cells survive even the most aggressive, cancer cell-killing therapy. It is assumed that such surviving cancer cell restore the cancer and cause the deadly metastases. This casts doubt on a therapeutic strategies that focus exclusively on cancer cell killing. Therefore, it was repeatedly postulated that, in addition to cancer cell killing, other (immune-) mechanisms are needed to control cancer (5, 6, 7).“ – as summarized by Professor Röcken.

The Tuebingen research team uncovered a critical, so far unknown immune mechanism that allows to permanently paralyze growing cancer cells. They showed for the first time that immune responses can cause a permanent growth arrest in cancers and also in single cancer cells (1). Scientifically this permanent growth arrest is termed senescence (2, 3).

Even under conditions where the immune system cannot kill the cancer, the two cytokines interferon (IFN) and tumor necrosis factor (TNF), may drive cancers into senescence. Thus, senescence induction causes a state, where ‚the cancer sleeps well controlled in his host’. This was first shown in an islet cancer of the pancreas (1, 4).

The same two cytokines, IFN and TNF, can drive a large number of mouse and human cancer cells into senescence. Clinically, this has two major consequences: Immune-induced senescence (figure 1) is obviously a physiological mechanism that contributes to the natural cancer control in humans (1). On the other side, recent data from cancer immune therapy suggest that the therapy is primarily efficient under conditions where the immune therapy causes permanent growth arrest of the metastases (8, 9).

Two mediators that are long known in cancer and infection immunology turn into the focus: interferon (IFN) and tumor necrosis factor (TNF). Many clinicians and researchers tried to destroy cancer and cancer-supplying vessels – like the Tuebingen researchers. Surprisingly, the Tuebingen group found that a certain combination of IFN and TNF protects mice from the development of islet cancers in the pancreas.

In the animals induction of senescence resulted in unexpectedly long protection from cancer (4). Even more important: when isolated from cancer prone animals, the ‘senescent cancer cells’ remained growth arrested without any further therapy, even when transferred into immune deficient, healthy mice. Thus, the senescent cancer cells had lost the aggressive behavior that characterizes cancer and remained well controlled (1).

This new therapeutic strategy offers the opportunity to develop new cancer immunotherapy that should be less aggressive, with relatively few side effects but highly efficient. Professor Rocken: „It is likely that in the future we will not primarily try to destroy cancer with ever more toxic regimen; instead we will focus on strategies that restore the body’s immune control over cancers “.

Media contact

Eberhard Karls University Tuebingen
Department of Dermatology
Prof. Dr. Martin Röcken
Liebermeisterstr. 25, 72076 Tuebingen
Tel. +49 (0)7071 29 84574
Fax +49 (0)7071/29 5450
1. Braumüller, H, Thomas Wieder, T, Brenner, E, Aßmann, S, Hahn, M, Alkhaled, M, Schilbach, K, Essmann, F, Kneilling, M, Griessinger, C, Ranta, F, Ullrich, S, Mocikat, R, Braungart, K, Mehra, T, Fehrenbacher, B, BerdeL, J, Meier, F, van den Broek, M, Häring, HU, Handgretinger, R, Quintanilla-Martinez, L, Fend, F, Pesic, M, Bauer, J, Zender, L, Schaller, M, Schulze-Osthoff, K, Röcken, M. T-helper-1-cell cytokines drive cancer into senescence.

Nature (online 04.02.2013). doi:10.1038/nature11824.

2. Michaloglou, C. et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724 (2005).
3. Braig, M. et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660-665 (2005).
4. Müller-Hermelink, N. et al. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 13, 507-518 (2008).
5. Sporn, MB. The war on cancer. The Lancet 347, 1377-1381 (1996).
6. Gatenby, RA. A change of strategy in the war on cancer. Nature 459, 508-509 (2009).

7. Röcken, M. Early tumor dissemination, but late metastasis: insights into tumor dormancy. J. Clin. Invest. 120, 1800-1803 (2010).

8. Walter S, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 18, 1254–1261 (2012).

9. Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 366; 2455-2465 (2012).

Dr. Ellen Katz | idw
Further information:

More articles from Health and Medicine:

nachricht ARTORG and Inselspital develop artificial pancreas
26.11.2015 | Universitätsspital Bern

nachricht Laboratory study: Scientists from Cologne explore a new approach to prevent newborn epilepsies
24.11.2015 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Tübinger Forscher entdecken neue Zelltypen im Gehirn

Untersuchung im Neocortex von Mäusen - Zusammenarbeit mit Wissenschaftlern aus Houston

Wissenschaftler aus Tübingen und Houston haben zahlreiche neue Zelltypen im Gehirn identifiziert. Im Neocortex von erwachsenen Mäusen führten sie erstmals eine...

Im Focus: Klimawandel: Forscher weisen dramatische Veränderung in den 1980er Jahren nach

Ende der 1980er Jahre erlebte die Erde eine dramatische Klimaveränderung. Sie umfasste die Tiefen der Ozeane ebenso wie die obere Atmosphäre und reichte vom Nord- bis zum Südpol. Ausgelöst durch den Ausbruch des Vulkans El Chichón in Mexico 1982 und verstärkt durch menschliches Handeln folgte daraus die größte Temperaturverschiebung der letzten 1.000 Jahre. Erstmals nachgewiesen hat dies ein internationales Forscherteam um Prof. Philip C. Reid von der Plymouth University und der Sir Alister Hardy Foundation for Ocean Science (UK). Die Ergebnisse wurden kürzlich in der Fachzeitschrift „Global Change Biology“ veröffentlicht.

Abrupte Klimaveränderungen haben oft dramatische Folgen für unseren Planeten. Dennoch sind sie in ihrer Art, ihrem Ausmaß und in ihrer Wirkungsweise meist nur...

Im Focus: Climate study finds evidence of global shift in the 1980s

Planet Earth experienced a global climate shift in the late 1980s on an unprecedented scale, fuelled by anthropogenic warming and a volcanic eruption, according to new research published this week.

Scientists say that a major step change, or ‘regime shift’, in the Earth’s biophysical systems, from the upper atmosphere to the depths of the ocean and from...

Im Focus: Innovative Photovoltaik – vom Labor an die Fassade

Fraunhofer ISE demonstriert neue Zell- und Modultechnologien an der Außenfassade eines Laborgebäudes

Das Fraunhofer-Institut für Solare Energiesysteme ISE hat die Außenfassade eines seiner Laborgebäude mit 70 Photovoltaik-Modulen ausgerüstet. Die Module...

Im Focus: Innovative Photovoltaics – from the Lab to the Façade

Fraunhofer ISE Demonstrates New Cell and Module Technologies on its Outer Building Façade

The Fraunhofer Institute for Solar Energy Systems ISE has installed 70 photovoltaic modules on the outer façade of one of its lab buildings. The modules were...

Alle Focus-News des Innovations-reports >>>



im innovations-report
in Kooperation mit academics

Bürger treffen Experten: Gespräch zu Chancen und Risiken der Nanotechnologie am 30.11.2015

27.11.2015 | Veranstaltungen

Arbeit in Sozialen Dienstleistungen - Welche Zukunft hat die Branche?

27.11.2015 | Veranstaltungen

Konzepte nutzergerechter Fahrerarbeitsplatzgestaltung

26.11.2015 | Veranstaltungen

Weitere VideoLinks >>>
Aktuelle Beiträge

Künstliche Herzklappe nach dem Vorbild der Natur

27.11.2015 | Förderungen Preise

Siemens liefert 126 Megawatt Onshore-Windleistung nach Schottland

27.11.2015 | Unternehmensmeldung

Hauptkläranlage Wien wird mit Siemens zum Ökokraftwerk

27.11.2015 | Energie und Elektrotechnik